OLVIG
PCVX icon

Oliver Lagore Vanvalin Investment Group’s Vaxcyte PCVX Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-80
Closed -$9.14K – 719
2024
Q3 		$9.14K Sell
80
-41
-34% -$3.69K ﹤0.01% 441
2024
Q2 		$9.14K Sell
121
-53
-30% -$3.61K ﹤0.01% 433
2024
Q1 		$11.9K Sell
174
-110
-39% -$7.62K ﹤0.01% 396
2023
Q4 		$17.8K Buy
284
+123
+76% +$6.39K 0.01% 331
2023
Q3 		$8.21K Sell
161
-24
-13% -$1.18K ﹤0.01% 470
2023
Q2 		$9.24K Buy
+185
New +$8.77K ﹤0.01% 474

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's PCVX Position: Q4 2024 in Review

Oliver Lagore Vanvalin Investment Group sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 80 shares — an estimated $9.14K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in PCVX in Q2 2023 and held it in 6 quarters. The position peaked at $17.8K in Q4 2023. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • Oliver Lagore Vanvalin Investment Group reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • Oliver Lagore Vanvalin Investment Group sold 80 Vaxcyte shares in Q4 2024, an estimated $9.14K.
  • Oliver Lagore Vanvalin Investment Group first reported a position in Vaxcyte in Q2 2023 and held it in 6 quarters.
  • Oliver Lagore Vanvalin Investment Group's Vaxcyte position peaked at $17.8K in Q4 2023.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q4 2024, filed 1 Apr 2025.